Funding - March 18, 2014
Karo Bio gets SEK 1 million from Vinnova
The company will be awarded 1 million SEK from Vinnova for the preclinical development of an ER-beta agonist for the treatment of multiple cancers. The grant will be awarded through Vinnova’s Forska & Väx program to finance toxicity and safety pharmacology studies of an ERbeta agonist. According to Karo Bio the compound has in previous […]
Collaboration - March 17, 2014
Novozymes Biopharma enters collaboration with Janssen
Novozymes Biopharma, part of Novozymes A/S has announced a collaboration with Janssen Research & Development, LLC. The agreement will enable Janssen to evaluate Novozymes Biopharma’s engineered albumin-based VELTIS™ technology for potential drug candidates. “We are delighted to be working with Janssen on this important collaboration,” says Svend Licht, Senior Director, Novozymes Biopharma in a press release. “The […]
Clinical Trials - March 14, 2014
Aprea initiates new study
Karolinska Development’s portfolio company Aprea is to evaluate its drug candidate for the treatment of ovarian cancer in a new British study. It is a phase 1b/II study on the pharmaceutical project APR-246, reports Life Science Sweden. The drug candidate is part of a new type of potential cancer drugs that lead the cancer cells […]
Collaboration - March 13, 2014
Denmark and Sweden join international collaborative program
Three regions from Denmark and Sweden are joining a prestigious international collaborative program announced by the Massachusetts Life Sciences Center. The partnering entities from Denmark and Sweden are Region Hovedstaden, Region Sjælland, Region Skåne, COBIS, Medicon Village and CAPNOVA. “We are very pleased that our regions now are a part of a program that gives Danish […]
Collaboration - March 13, 2014
Medimmune collaborates with University of Cambridge
Medimmuneand the University of Cambridge have entered into a three-year oncology research collaboration. The aim of the partnership is to advance cancer research by using imaging technologies to measure key biologic changes within growing tumours. Under the agreement, Medimmune will contribute both funding and a post-doctoral scientist to work within the laboratory of Professor Kevin Brindle at […]
Agreement - March 12, 2014
Orexo enters agreement for Zubsolv
Orexo AB has announced a multi-year agreement with UnitedHealth Group and OptumRx providing preferred coverage and reimbursement of Zubsolv. Zubsolv is a sublingual tablet formulation for maintenance treatment of opioid dependence. Under the agreement, the product will be given preferred, Tier 2 brand status on UnitedHealth Group commercial employer and individual formularies managed by OptumRx for […]
